Designs for Group Sequential Phase II Clinical Trials
From MaRDI portal
(Redirected from Publication:3201547)
Recommendations
Cited in
(27)- A review of phase 2-3 clinical trial designs
- Designs for randomized phase II clinical trials with two treatment arms
- Nearly optimal truncated group sequential test on binomial proportions
- An Optimal Design for Screening Trials
- Optimal Designs for a Grouped Sequential Binomial Trial
- On the maximum total sample size of a group sequential test about bivariate binomial propor\-tions
- Optimal sequential designs in phase I studies
- MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
- Improving the flexibility and efficiency of phase II designs for oncology trials
- Exact confidence limits after a group sequential single arm binary trial
- On the maximum total sample size of a group sequential test about binomial proportions.
- A novel Phase II single-arm hybrid design to minimize trial duration and enhance subsequent Phase III trial success rate
- Approximately optimal designs for phase II clinical studies
- Bayesian safety and futility monitoring in phase II trials using one utility-based rule
- Design and Analysis of Phase II Cancer Trials: A Review of Statistical Methods and Guidelines for Medical Researchers
- Optimal adaptive two-stage designs for phase II cancer clinical trials
- Stopping rules for phase II clinical trials: an overview
- Two-Stage Designs with Additional Futility Tests for Phase II Clinical Trials with Heterogeneous Patient Populations
- Methodology and application of adaptive and sequential approaches in contemporary clinical trials
- Two-stage group sequential designs for comparative clinical trials
- On Bayesian estimators in multistage binomial designs
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- A class of confidence intervals for sequential phase II clinical trials with binary outcome
- Computation of optimal group sequential designs
- Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
- Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials
- Assurance test and its equivalent truncated sequential test
This page was built for publication: Designs for Group Sequential Phase II Clinical Trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3201547)
